Cardiff Oncology
CRDF
Market cap $147M

2.21 USD

-0.11

4.74%

At close Aug 25, 4:00 PM EDT

Pre-market

2.23

+0.02

0.90%

1 day

-4.74%

5 days

-9.43%

1 month

-44.33%

3 months

-28.71%

6 months

-47.75%

Year to date

-48.12%

1 year

-7.92%

5 years

-70.92%

10 years

-99.44%

About: Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Employees: 33

Healthcare Biotechnology

0

Funds holding %

of 7,429 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

231% more call options, than puts

Call options by funds: $3.54M | Put options by funds: $1.07M

91% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 23

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

3% less funds holding

Funds holding: 116 [Q1] → 112 (-4) [Q2]

6.39% less ownership

Funds ownership: 48.62% [Q1] → 42.23% (-6.39%) [Q2]

13% less capital invested

Capital invested by funds: $102M [Q1] → $88.5M (-$13.1M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3.50

58%

upside

Avg. target

$10.83

390%

upside

High target

$19

760%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

HC Wainwright & Co. Robert Burns	352%upside $10	Buy Maintained	6 Aug 2025
Ladenburg Thalmann	760%upside $19	Buy Initiated	8 Jul 2025
Jefferies Maury Raycroft	58%upside $3.50	Hold Initiated	24 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CRDF published over the past 30 days

The Motley Fool

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. CRDF on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC).

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Cardiff Oncology: Data Update Resolves Some Signals

Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, reflecting typical regression to the mean and leaving some questions unanswered until the next update in Q1 2026. CRDF's cash position is stable for now, but a future financing need is likely as the company advances toward a pivotal phase 3 trial.

Cardiff Oncology: Data Update Resolves Some Signals

Zacks Investment Research

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) –

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans.

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology Names Roger Sidhu as Medical Chief

Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Zacks Investment Research

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

See News Rankings

Charts implemented using Lightweight Charts™